Xeris Pharmaceuticals Inc (XERS) — Capital Reinvestment Ratio
Latest as of March 2026:
0.03x
Xeris Pharmaceuticals Inc (XERS) has a Capital Reinvestment Ratio of 0.03x as of March 2026, meaning it reinvests 0% of its operating cash flow ($9.87 Million) in capital expenditures ($325.00K). See XERS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.03x
Capex / Operating Cash Flow
Operating Cash Flow
$9.87 Million
USD
Capital Expenditures
$325.00K
USD
Data as of
Mar 2026
Most recent filing
Xeris Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks Xeris Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Xeris Pharmaceuticals Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for Xeris Pharmaceuticals Inc from 2025 to 2025. For live market cap and broader valuation context, see Xeris Pharmaceuticals Inc (XERS) total market value.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | $28.63 Million | $696.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow